» Articles » PMID: 33930707

Essential Considerations During Vaccine Design Against COVID-19 and Review of Pioneering Vaccine Candidate Platforms

Overview
Date 2021 Apr 30
PMID 33930707
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

The calamity of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), COVID-19, is still a global human tragedy. To date, no specific antiviral drug or therapy has been able to break the widespread of SARS-CoV2. It has been generally believed that stimulating protective immunity via universal vaccination is the individual strategy to manage this pandemic. Achieving an effective COVID-19 vaccine requires attention to the immunological and non-immunological standpoints mentioned in this article. Here, we try to introduce the considerable immunological aspects, potential antigen targets, appropriate adjuvants as well as key points in the various stages of COVID-19 vaccine development. Also, the principal features of the preclinical and clinical studies of pioneering COVID-19 vaccine candidates were pointed out by reviewing the available information. Finally, we discuss the key challenges in the successful design of the COVID-19 vaccine and address the most fundamental strengths and weaknesses of common vaccine platforms.

Citing Articles

Efficacy and safety of a novel antiviral herbal preparation in ICU-admitted patients with COVID-19: A phase III double-blinded controlled trial.

Avicenna J Phytomed. 2024; 14(2):215-228.

PMID: 38966633 PMC: 11221769. DOI: 10.22038/AJP.2023.23259.


Immunoinformatics design of a structural proteins driven multi-epitope candidate vaccine against different SARS-CoV-2 variants based on fynomer.

Sarvmeili J, Baghban Kohnehrouz B, Gholizadeh A, Shanehbandi D, Ofoghi H Sci Rep. 2024; 14(1):10297.

PMID: 38704475 PMC: 11069592. DOI: 10.1038/s41598-024-61025-2.


Molecular Mimicry of the Viral Spike in the SARS-CoV-2 Vaccine Possibly Triggers Transient Dysregulation of ACE2, Leading to Vascular and Coagulation Dysfunction Similar to SARS-CoV-2 Infection.

Devaux C, Camoin-Jau L Viruses. 2023; 15(5).

PMID: 37243131 PMC: 10222462. DOI: 10.3390/v15051045.


Therapeutic and diagnostic applications of nanoparticles in the management of COVID-19: a comprehensive overview.

Gholizadeh O, Yasamineh S, Amini P, Afkhami H, Delarampour A, Akbarzadeh S Virol J. 2022; 19(1):206.

PMID: 36463213 PMC: 9719161. DOI: 10.1186/s12985-022-01935-7.


: Membrane and Non-Membrane Protein Structure, Function, Immune Response Interaction, and Vaccine Development.

Jasni N, Saidin S, Weng Kin W, Arifin N, Othman N Membranes (Basel). 2022; 12(11).

PMID: 36363634 PMC: 9695907. DOI: 10.3390/membranes12111079.


References
1.
Roper R, Rehm K . SARS vaccines: where are we?. Expert Rev Vaccines. 2009; 8(7):887-98. PMC: 7105754. DOI: 10.1586/erv.09.43. View

2.
Pardi N, Hogan M, Porter F, Weissman D . mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018; 17(4):261-279. PMC: 5906799. DOI: 10.1038/nrd.2017.243. View

3.
Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y . Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clin Infect Dis. 2020; 71(16):2027-2034. PMC: 7184337. DOI: 10.1093/cid/ciaa344. View

4.
Enayatkhani M, HasaniAzad M, Faezi S, Gouklani H, Davoodian P, Ahmadi N . Reverse vaccinology approach to design a novel multi-epitope vaccine candidate against COVID-19: an study. J Biomol Struct Dyn. 2020; 39(8):2857-2872. PMC: 7196925. DOI: 10.1080/07391102.2020.1756411. View

5.
Netland J, DeDiego M, Zhao J, Fett C, Alvarez E, Nieto-Torres J . Immunization with an attenuated severe acute respiratory syndrome coronavirus deleted in E protein protects against lethal respiratory disease. Virology. 2010; 399(1):120-128. PMC: 2830353. DOI: 10.1016/j.virol.2010.01.004. View